Authors’ Reply

Andrew J.B. Watts; Keith H. Keller; Astrid Weins

doi:10.1681/ASN.2021121540

We are excited by the renewed focus on diffuse podocytopathies that our discoveries are eliciting in the field.¹ We agree that gaining a more precise mechanistic understanding of disease pathogenesis is crucial, and that developing a new classification for diffuse podocytopathies on the basis of autoantibodies is important for guiding precision medicine strategies to treat these diseases.² We strongly encourage contributions from all groups in the field, together with independent validation of all of the proposed factors, to ensure the pathogenic significance of diffuse podocytopathies is confirmed.

Disclosures

A. Weins reports having consultancy agreements with Goldfinch Bio, Inc. All remaining authors have nothing to disclose.

Funding

None.

Footnotes

Published online ahead of print. Publication date available at www.jasn.org.
See related letter to the editor, “Autoimmune Podocytopathies: A Novel Sub-Group of Diseases from Childhood Idiopathic Nephrotic Syndrome,” on pages 653–654, and original article, “Discovery of Autoantibodies Targeting Nephrin in Minimal Change Disease Supports a Novel Autoimmune Etiology,” in Vol. 33, Iss. 1, on pages 238–252.

References

↵
1. Ye Q,
2. Zhou C,
3. Wang D,
4. Fu H,
5. Wang J,
6. Mao J
: Seven novel podocyte autoantibodies were identified to diagnosis a new disease subgroup-autoimmune Podocytopathies. Clin Immunol 232: 108869, 2021
OpenUrl
↵
1. Watts A,
2. Keller K,
3. Lerner G,
4. Rosales I,
5. Collins A,
6. Sekulic M, et al
: Discovery of autoantibodies targeting nephrin in minimal change disease supports a novel autoimmune etiology. J Am Soc Nephrol 33: 238–252, 2022
OpenUrl Abstract/FREE Full Text